Session I: Acute Lymphoblastic Leukemia 

Session Chairs: Selina Luger, MD and Ching-Hon Pui, MD  

Welcome and Opening Remarks | John DiPersio, MD, PhD | President, Society of Hematologic Oncology

Risk Stratification in ALL in Light of the Advances in Immunotherapy | Charles G. Mullighan, MBBS (Hons), MSc, MD | St. Jude Children's Research Hospital, Memphis, Tennessee, USA

Optimal Management of CNS Relapses | LaQuisa Hill, MD | Baylor College of Medicine, Houston, Texas, USA

Optimal Management of Philadelphia-Positive ALL and New Horizons | Josep-Maria Ribera, MD, PhD | Catalan Institute of Oncology, Barcelona, Spain

CAR T-Cell Therapy: A Consolidation Approach or a Bridge to Allogeneic Stem Transplantation | Jae Park, MD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Management of Resistant B-ALL: Novel Agents | Aaron C. Logan, MD, PhD, MPhil | University of California, San Francisco, California, USA

Debate: It Is Time to Move Into Less Chemotherapy and Chemotherapy-Free Regimens in Frontline ALL- PRO | Hagop Kantarjian, MD | MD Anderson Cancer Center, Houston, Texas, USA

Debate: It Is Time to Move Into Less Chemotherapy and Chemotherapy-Free Regimens in Frontline ALL- CON | Rob Pieters, MD, MSc, PhD | Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands

Oral Abstract | TBD | Speaker | Affiliation